Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transient neonatal myasthenia gravis.

O Papazian1

  • 1Department of Neurology, Miami Children's Hospital, FL 33155.

Journal of Child Neurology
|April 1, 1992
PubMed
Summary

Transient neonatal myasthenia gravis affects 21% of infants born to mothers with acquired myasthenia gravis. Diagnosis relies on response to acetylcholinesterase agents, with most infants recovering spontaneously.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Training of executive function in preschool children with combined attention deficit hyperactivity disorder: a prospective, controlled and randomized trial].

Revista de neurologia·2009
Same author

[Treatment of herpes simplex encephalitis in children].

Revista de neurologia·2006
Same author

[Cerebrovascular accidents in full-term newborn infants].

Revista de neurologia·2006
Same author

[Executive function disorders].

Revista de neurologia·2006
Same author

[Hyperbaric oxygen treatment for children with cerebral palsy].

Revista de neurologia·2003
Same author

[Generalized neonatal hypotonia].

Revista de neurologia·2003

Area of Science:

  • Neonatal Neurology
  • Neuromuscular Disorders
  • Immunology

Background:

  • Transient neonatal myasthenia gravis (TNMG) is a neuromuscular transmission defect affecting infants of mothers with acquired myasthenia gravis.
  • While passive-transfer acetylcholine receptor (AChR) antibodies are present in many newborns, their direct pathogenic role is uncertain as not all infants are symptomatic.
  • The pathogenesis in infants without AChR antibodies remains unknown, and prenatal diagnostic markers are lacking.

Purpose of the Study:

  • To investigate the characteristics and diagnostic approaches for transient neonatal myasthenia gravis.
  • To explore potential prenatal diagnostic tools for identifying at-risk newborns.
  • To understand the role of AChR antibodies and other factors in the pathogenesis of TNMG.

Main Methods:

  • Review of clinical presentation and diagnostic criteria for TNMG.
  • Analysis of the correlation between maternal and neonatal AChR antibody titers.
  • Evaluation of potential diagnostic markers, including HLA typing.

Main Results:

  • TNMG occurs in 21% of infants born to mothers with acquired myasthenia gravis.
  • Common symptoms include difficulties with sucking, swallowing, and respiration within the first day of life.
  • Diagnosis is confirmed by transient improvement with acetylcholinesterase agents; supportive management is required in approximately 80% of cases.

Conclusions:

  • Transient neonatal myasthenia gravis is a significant concern in infants of affected mothers.
  • Acetylcholinesterase agents are crucial for diagnosis and management, with most cases resolving spontaneously.
  • Further research into pathogenesis and prenatal identification, potentially using HLA typing, is warranted.

Related Experiment Videos